Ashirbekov Yeldar, Abaildayev Arman, Omarbayeva Nazgul, Botbayev Dauren, Belkozhayev Ayaz, Askandirova Anel, Neupokoyeva Alena, Utegenova Gulzhakhan, Sharipov Kamalidin, Aitkhozhina Nagima
M. Aitkhozhin Institute of Molecular Biology and Biochemistry, Almaty, Kazakhstan.
Kazakh Research Institute of Oncology and Radiology, Almaty, Kazakhstan.
PeerJ. 2020 Dec 16;8:e10494. doi: 10.7717/peerj.10494. eCollection 2020.
Breast cancer (BC) is the most common cancer among women worldwide. At present, there is a need to search for new, accurate, reliable, minimally invasive and cheap biomarkers in addition to existing methods for the diagnosis and prognosis of BC. The main goal of this study was to test the diagnostic value of six circulating miRNAs in Kazakh women.
TaqMan-based miRNA profiling was conducted using plasma specimens from 35 BC women patients and 33 healthy women samples (control group).
The level of all seven miRNAs (including endogenous control) normalized by synthetic cel-miR-39 were significantly elevated in the group of BC patients. Normalization using miR-222-3p as endogenous control reduced differences in level of miRNAs between groups; as a result, only three miRNAs were significantly upregulated in the group of BC patients-miR-145-5p ( = 6.5e-12), miR-191-5p ( = 3.7e-10) and miR-21-5p ( = 0.0034). Moreover, ROC analysis showed that the use of miR-145-5p and miR-191-5p, both individually (AUC = 0.931 and 0.904, respectively) or in combination (AUC = 0.984), allows to accurately differentiate BC patients from healthy individuals.
Two plasma miRNAs-miR-145-5p and miR-191-5p-are potential biomarkers for diagnosis of BC in the Kazakh population. The findings need to be further substantiated using a more representative sample.
乳腺癌(BC)是全球女性中最常见的癌症。目前,除了现有的乳腺癌诊断和预后方法外,还需要寻找新的、准确、可靠、微创且廉价的生物标志物。本研究的主要目的是检测六种循环miRNA在哈萨克族女性中的诊断价值。
使用来自35例乳腺癌女性患者和33例健康女性样本(对照组)的血浆标本进行基于TaqMan的miRNA分析。
通过合成的cel-miR-39标准化后,所有七种miRNA(包括内参)的水平在乳腺癌患者组中均显著升高。以miR-222-3p作为内参进行标准化可减少组间miRNA水平的差异;结果,在乳腺癌患者组中只有三种miRNA显著上调——miR-145-5p(P = 6.5e-12)、miR-191-5p(P = 3.7e-10)和miR-21-5p(P = 0.0034)。此外,ROC分析表明,单独使用miR-145-5p和miR-191-5p(AUC分别为0.931和0.904)或联合使用(AUC = 0.984),均可准确区分乳腺癌患者和健康个体。
两种血浆miRNA——miR-145-5p和miR-191-5p——是哈萨克族人群中乳腺癌诊断的潜在生物标志物。这些发现需要使用更具代表性的样本进一步证实。